Name: BBIO Income Statement - Bridgebio Pharma Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

BBIO - Bridgebio Pharma, Inc.

USD | NASDAQ | Healthcare

BBIO Income Statement - Bridgebio Pharma Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q3 FY 18
Revenues
Revenues	194.5	154.2	120.7	110.6	116.6	5.9	2.7	2.2	211.1	1.7	4.1	1.6	1.8	1.9	0.3	73.7

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
Revenues
Revenues	580.0	502.1	221.9	9.3	77.6	69.7	8.2	40.6	-	-
Cost of Revenue	28.3	21.0	3.9	2.4	3.4	3.1	-	-	-	-
Gross Profit	551.7	481.1	218.0	6.9	74.2	66.6	-	-	-	-
Operating Expenses
Research & Development	467.2	452.0	506.5	455.7	399.5	451.0	337.0	209.9	140.1	30.6
Selling General & Administrative	588.8	531.2	288.9
Operating Income
Operating Income	(525.0)	(523.4)	(593.0)	(607.4)	(512.2)	(576.6)	(474.5)	(266.2)	(183.7)	(43.9)
Non-Operating
Interest Income	20.7	19.9	17.2	18.0	7.5	1.1	4.0	8.9	2.0	0.0
Interest Expense	47.9	53.1	91.0	81.3
Tax & Net
Income Tax Expense	-	0.4	1.2	0.0	0.0	-	-	-	-	-
Net Income From Continuing Ops	(729.9)	(732.9)	(543.3)
Per Share
EPS Basic	(3.70)	(3.78)	(2.88)	(3.95)	(3.26)	(3.90)	(3.80)	-	-	-
EPS Diluted	(3.70)	(3.78)	(2.88)	(3.95)
Supplementary Data
EBITDA	-	(518.0)	(586.9)	(600.9)	(505.4)	(570.8)	(473.0)	(265.4)	-	-
EBIT	(525.0)	(523.4)	(593.0)	(607.4)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Operating Expenses
Research & Development	126.6	116.4	112.9	111.2	111.4	130.4	120.4	114.7	141.0	130.2	125.1	107.5	92.9	90.9	92.5	108.4	107.6	122.2	104.3	102.0	122.6	90.2	92.1	86.6	68.2	57.5	55.3	52.3	44.9	31.1
Selling General & Administrative	163.9	158.1	137.6	129.2	106.4	94.8	68.8	59.5	65.8	47.6	35.8	36.1	31.1	31.9	31.2	36.4
Selling & Marketing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General & Administrative	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation & Amortization	1.2	-	-	-	1.3	-	-	-	1.6	-	-	-	1.6	-	-	-
Amortization of Intangibles	0.7	0.7	0.7	0.7	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.3	0.6	0.6	0.9
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	300.5	293.7	265.9	244.8	221.0	231.9	194.5	177.7	210.8	179.2	161.8	147.7	128.0	131.1	129.5	153.9

Operating Income
Operating Income	(106.0)	(139.6)	(145.2)	(134.3)	(104.4)	(226.0)	(191.8)	(175.5)	0.3	(177.4)	(157.7)	(146.1)	(126.2)	(129.2)	(129.1)	(80.2)	(173.7)	(165.6)	(149.5)	(94.0)	(167.5)	(127.5)	(119.9)	(124.6)	(102.5)	(78.6)	(54.5)	(69.3)	(63.8)	(41.5)

Non-Operating
Interest Income	6.2	4.3	6.2	3.9	5.4	4.7	3.3	5.2	4.1	5.6	3.8	4.5	4.2	4.1	2.4	0.8	0.3	0.2	0.2	0.3	0.4	0.4	0.7	0.9	1.9	2.4	2.7	1.7	2.1	0.5
Interest Expense	12.9	(14.4)	11.7	37.6	18.1	21.5	23.1	22.9	23.5	20.3	20.3	20.6	20.1	20.0	19.8	20.3	20.3	15.1
Income From Equity Investments	(18.3)	(21.0)	(15.8)	(20.2)	(15.6)	(16.7)	(6.6)	(7.9)	0.0	-	0.0	0.0	-	-	-	-
Other Non-Operating Income	(60.6)	(55.2)	(41.3)	(47.4)	(65.2)	(40.2)	27.5	100.0	(36.5)	7.1	(21.8)	(14.6)	(16.6)	(11.3)	(11.1)	77.6	(27.7)
Pre-Tax Income	-	-	(186.5)	(181.7)	-	-	(164.3)	(75.5)	-	-	-	-	-	-	-	-	-

Tax & Net
Income Tax Expense	-	(0.1)	(1.5)	2.1	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-	0.0	0.0	0.0	-	0.0	0.0	0.0	-	-	-	-	-
Net Income From Continuing Ops	(166.6)	(194.6)	(184.9)	(183.8)	(169.6)	(267.4)	(164.3)	(75.5)	(36.2)	(170.3)	(179.5)	(160.7)	(142.7)	(140.6)	(140.2)	(2.6)	(201.3)
Net Income From Discontinued Ops	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	(166.6)	(194.6)	(184.9)	(183.8)	(169.6)	(267.4)	(164.3)	(75.5)	(36.2)	(170.3)	(179.5)	(160.7)	(142.7)	(140.6)	(140.2)	(2.6)	(201.3)
Net Income Attributable To Parent	(164.0)	(192.9)	(182.7)	(181.9)	(167.4)	(265.1)	(162.0)	(73.5)	(35.2)	(168.1)	(177.0)	(157.9)	(140.2)	(137.6)	(137.3)	(9.9)
Less: Minority Interest	(2.5)	(1.8)	(2.2)	(1.9)	(2.2)	(2.3)	(2.2)	(2.1)	(0.9)	(2.2)	(2.5)	(2.8)	(2.6)	(3.0)	(2.9)	7.3	(4.9)
Less: Preferred Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income To Common Shareholders	(164.0)	(192.9)	(182.7)	(181.9)	(167.4)	(265.1)	(162.0)	(73.5)	(35.2)	(168.1)	(177.0)	(157.9)	(140.2)	(137.6)	(137.3)

Per Share
EPS Basic	(0.84)	-	(0.95)	(0.95)	(0.88)	-	(0.86)	(0.39)	(0.20)	-	(1.08)	(0.98)	(0.92)	-	(0.93)	(0.07)	(1.35)	-	(1.06)	(0.66)	-	-	-	-	-	-	-	-	-	-
EPS Diluted	(0.84)	-	(0.95)	(0.95)	(0.88)	-	(0.86)	(0.39)	(0.20)	-	(1.08)	(0.98)	(0.92)	-	(0.93)	(0.07)	(1.35)	-
Shares Basic	194.8	-	191.9	190.5	190.1	-	188.5	187.6	178.7	-	163.3	160.5	152.6	-	147.9	146.7	145.9	-
Shares Diluted	194.8	-	191.9	190.5	190.1	-	188.5	187.6	178.7	-	163.3	160.5	152.6	-	147.9	146.7	145.9	-

Supplementary Data
EBITDA	(104.8)	-	-	-	(103.1)	-	-	-	1.9	-	-	-	(124.5)	-	-	-	(171.8)	-	-	-	(166.9)	-	-	-	-	-	-	-	-	-
EBIT	(106.0)	(139.6)	(145.2)	(134.3)	(104.4)	(226.0)	(191.8)	(175.5)	0.3	(177.4)	(157.7)	(146.1)	(126.2)	(129.2)	(129.1)	(80.2)	(173.7)	(165.6)	(149.5)